Email this article Hodgkin's lymphoma relapses and refractory forms therapy variants in children, adolescents and young adults
- Authors: Pshonkin A.V.1, Evstratov D.A.1, Myakova N.V.1
-
Affiliations:
- Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
- Issue: Vol 17, No 1 (2018)
- Pages: 136-143
- Section: Статьи
- Submitted: 09.08.2018
- Published: 09.02.2018
- URL: https://hemoncim.com/jour/article/view/39
- DOI: https://doi.org/10.24287/1726-1708-2018-17-1-136-143
- ID: 39
Cite item
Full Text
Abstract
Hodgkin lymphoma has been studied more than any other type of lymphoma. The result of those studies has lead to rapid advances in the diagnosis and treatment of the disease. The vast majority of Hodgkin lymphoma patients can be cured after first line treatment. And even for those patients who relapse or become refractory, secondary therapies are often successful in providing another remission and cure the patient. The prescribed type of treatment for individual patients depends on several factors, such as time of relapse occurance, the patient’s age, overall health and previous therapies received.
About the authors
A. V. Pshonkin
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
Author for correspondence.
Email: alexey.pshonkin@gmail.com
ORCID iD: 0000-0002-2057-2036
MD, pediatric hematologist/oncologist, head of Outpatient Department
Russia 117997, Moscow, Samory Mashela st., 1
+7 (495) 287-6570
D. A. Evstratov
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyRussian Federation
N. V. Myakova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-4779-1896
Russian Federation
References
Supplementary files
